After receiving my Ph.D. in Biochemistry from UCSD and a NIH postdoctoral fellowship at the University of Utah, I joined ImmunoGen, a biotechnology company in the Boston area focused on developing Antibody-Drug Conjugates (ADCs). During my 11 years at ImmunoGen I had the opportunity to contribute to the advancement of several ADCs into the clinic including KadcylaTM which was approved for the treatment of patients with metastatic breast cancer in 2013. In 2014 I joined Genentech where I currently lead a group focused on the production and characterization of novel proteins and conjugates for therapeutic applications such as engineered antibodies, antibody fragments, chemically-linked multimers, and ADCs.